Why I Hate AstraZeneca plc

Aside from its 5.6% yield, Harvey Jones finds little to love about AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There is something to love and hate in almost every stock, but sometimes the hate outweighs the love. Today, that’s the case with AstraZeneca (LSE: AZN) (NYSE: AZN.US). Here are five reasons why.

Where did the growth go? 

If you had invested in AstraZeneca three years ago, you would now be sitting on a loss of nearly 5%. In that time, the FTSE 100 rose 15% and pharmaceutical rival GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) was up a healthy 22%. That’s serious underperformance by AZN. The slide has continued with a 6% fall in the past six months, against a 5% rise on the FTSE 100. Reversing this will take time.

Too much bad news

Most companies like to bury the bad news in their results. AstraZeneca doesn’t have that luxury. Its recent results headlined a 4% drop in Q2 revenue to $6.23 billion, largely due to loss of exclusivity on several key brands, which wiped out around $500 billion of revenue. Core operating profit was down 10% to $2.06 billion, while core earnings per share (EPS) fell 21% to $1.20. Pricing pressure in Europe hasn’t helped, either. You can praise management for its honesty, if little else.

It’s a long road to recovery

Pascal Soriot, chief executive officer, has put on a brave face, claiming “real progress” against AZN’s strategic priorities, with its investment in distinctive science, pipeline projects and key markets delivering double-digit revenue growth. Bringing new prescription drugs to market is a precarious business, with many a slip between pipeline and profit. As a pure pharmaceuticals group, without the diversification that Glaxo’s consumer healthcare division gives it, AstraZeneca has to get this right.

This stock is all yield

One of the benefits of a falling share price is a rising yield, so you won’t be surprised to see that AstraZeneca now yields a highly likeable 5.6%, against Glaxo’s 4.7%. But what I don’t like is that the first interim dividend was exactly the same as last year. No progression there. Management also decided there would be no share repurchases this year, claiming it can put the money to better use by investing in the business. Let’s hope so.

Growth still looks scarce

AstraZeneca is on a forecast 21% drop in earnings per share (EPS) this calendar year. 2014 should see a smaller fall of 6%, but that’s still a fall. Throw in a 12% drop in 2012, and EPS look set to fall across three consecutive years. The result is that you can buy AZN at just 7.8 times earnings, almost half Glaxo’s valuation of 14 times earnings. AstraZeneca may suit patient contrarians, but these embarrassing figures show just how far it has fallen behind its big rival in recent years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Harvey owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

 
 

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »